A major goal was to design a promoter specific for rhabdomyosarcoma cells over myogenic cells, and while we increased rhabdomyosarcoma specificity with our ∆MEF3/NF1 MYOGENIN promoter, there remains residual toxicity in myoblasts. This evidence concerns the gene NF1 and rhabdomyosarcoma.